Alzheimer's disease, a major and increasing global health challenge, is an irreversible,
progressive form of dementia, associated with an ongoing decline of brain functioning. The …

Alzheimer's disease (AD) is well-known as a severe neurodegeneration disease involving
complicated etiologies, and cholinesterase inhibition remain the prevailing mode of clinical …

Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …

Current pharmacotherapy for Alzheimer's disease involves compounds that are aimed at
increasing the levels of acetylcholine in the brain by facilitating cholinergic …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and
cognitive loss, and represents the leading cause of dementia in elderly people. Besides the …

In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During
the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to …

The pathophysiology of Alzheimer's disease is complex and involves several different
biochemical pathways. These include defective β-amyloid (Aβ) protein metabolism …

Alzheimer's Disease (AD) is the most common cause for dementia in our ageing population,
which leads to a slowly progressive, irretrievable ruination of mental function. The …

Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the
presynaptic markers of the cholinergic system in the brain areas related to memory and …

Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …